Phase I/IIa Study of Intratumoral/Intracerebral or Intravenous/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2018
At a glance
- Drugs H 1PV (Primary) ; H 1PV (Primary) ; H 1PV (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oryx GmbH & Co
- 16 May 2018 Results presented in the GmbH & Co media release.
- 16 May 2018 According to an Oryx GmbH & Co media release, data from this trial will be presented at the 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT) (May 20118).
- 06 Nov 2017 According to an Oryx GmbH & Co media release, results from this trial will be published in the peer-reviewed medical journal, Molecular Therapy.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History